Item 7.01 Regulation FD Disclosure.

Dr. Claire Kruger, Chief Executive Officer, and Dr. Robert Lodder, President, will deliver a company presentation to various prospective investors at the Rodman & Renshaw 14th Annual Healthcare Conference at 11:40 a.m. Eastern time on Monday, September 10, in the North Foyer of the Waldorf Astoria in New York. The overview will introduce the Spherix DDDAS combination drug development platform, and reveal how the platform led to the latest advances in the SPX106T development program, including new uses of SPX106T to slow the growth rate of abdominal aortic aneurysms as well as to treat other diseases with inflammatory components. The presentation is available on the Company's website at www.spherix.com, is attached hereto as Exhibit 99.1, and is incorporated herein by reference.